Chronic PPAR-gamma Agonist Treatment Increases Fibrillar Amyloidosis but Improves Cognition in a Mouse Model of Alzheimer's disease

M Deussing,T Blume,F Peters,B Zott, C Schmidt,Y Shi, G Kleinberger, C Focke, S Lindner,FJ Gildehaus, L Beyer, B Ungern-Sternberg,P Bartenstein,K Baumann,M Dorostkar, C Haass, H Adelsberger,A Rominger,J Herms,M Brendel

57. Jahrestagung der Deutschen Gesellschaft für NuklearmedizinNuklearmedizin（2019）

引用 0|浏览2

暂无评分

摘要

Immunmodulatory treatment with the PPAR-gamma agonist Pioglitazone shows heterogeneous results in Alzheimer's disease (AD). We aimed to apply longitudinal in-vivo PET monitoring to identify predictive factors for treatment response.

查看译文

关键词

Neurodegeneration

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要